Skip to main content

Table 2 Schedule of visits and assessments at different points of the study protocol

From: FOVOCIP study: a multicenter randomized trial of fosfomycin versus ciprofloxacin for febrile neutropenia in hematologic patients—efficacy and microbiologic safety

Procedures

Screening visit

Daya 1

Day 8 ± 1

Day 15 ± 2

Day 22 ± 2

Day 29 ± 2

End of treatment

Informed consent form

X

      

Inclusion/exclusion criteria

X

      

Randomization

 

X

     

Demographic data

X

      

Medical history

X

      

Size

X

      

Weight

X

X

X

X

X

X

X

Physical examination: vital signs

X

X

X

X

X

X

X

ECOG

X

     

X

Electrocardiogram

X

X

X

X

X

X

X

Study treatment

 

x

x

x

x

x

 

Hemogram

X

X

X

X

X

X

X

Biochemistry

X

X

X

X

X

X

X

Coagulation

X

X

X

X

X

X

X

Pregnancy test

X

      

Concomitant medication/antimicrobials

X

X

X

X

X

X

X

Adverse effects

 

X

X

X

X

X

X

Microbiological culture

X

X

X

X

X

X

X

Stool sample for microbiome analysis

X

     

Xb

  1. aWhen less than 72 h have elapsed between the screening visit and day 1, it will not be necessary to repeat the electrocardiogram or laboratory studies, including microbiological studies
  2. bIn case the patient is unable to collect stool before receiving the first dose of empirical antibacterials, a rectal exudate will be taken with a swab